Effects of nintedanib by inclusion criteria for progression of interstitial lung disease

The INBUILD trial investigated nintedanib placebo in patients with progressive fibrosing interstitial lung diseases (ILDs). We investigated the decline in forced vital capacity (FVC) in subgroups based on the inclusion criteria for ILD progression. Subjects had a fibrosing ILD other than idiopathic...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The European respiratory journal 2022-02, Vol.59 (2), p.2004587
Hauptverfasser:	Maher, Toby M, Brown, Kevin K, Kreuter, Michael, Devaraj, Anand, Walsh, Simon L F, Lancaster, Lisa H, Belloli, Elizabeth A, Padilla, Maria, Behr, Juergen, Goeldner, Rainer-Georg, Tetzlaff, Kay, Schlenker-Herceg, Rozsa, Flaherty, Kevin R
Format:	Artikel
Sprache:	eng
Schlagworte:	Original s
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!